EAN 2022 | Early initiation of high-efficacy DMTs in MS
Massimo Filippi, MD, Vita-Salute San Raffaele University, Milan, Italy, shares his perspective on using high-efficacy disease-modifying therapies (DMts) at the initial stages of multiple sclerosis (MS). It is established that MS treatment should be started as early as possible. Nowadays, the debate has changed to whether early treatment should also be high-efficacy treatment. Early initiation of high-efficacy DMTs may be the best strategy to delay irreversible neurological damage and progression of the disease. Moreover, high-efficacy DMTs may positively impact overall cost-effectiveness and healthcare systems sustainability. This interview took place at the 2022 Congress of the European Academy of Neurology (EAN) in Vienna, Austria.
Disclosures
Editor in Chief of the Journal of Neurology, Associate Editor of Human Brain Mapping, Associate Editor of Radiology, and Associate Editor of Neurological Sciences;
Compensation for consulting services and/or speaking activities from Alexion, Almirall, Bayer, Biogen, BMS, Celgene, Chiesi Italia, Eli Lilly, Genzyme, Janssen, Merck-Serono, Neopharmed Gentili, Novartis, Roche, Sanofi, Takeda, and Teva Pharmaceutical Industries;
Research support from Biogen Idec, Merck-Serono, Novartis, Roche, Teva Pharmaceutical Industries, Italian Minsitry of Health, Fondazione Italiana Sclerosi Multipla, and ARiSLA.
